Aprepitant: novel antiemetic brings greater benefit for chemotherapy recipients

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1400, 2003-01, pp. : 11-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The neurokinin₁ receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy

By Warr David

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 12, 2006-08 ,pp. : 1653-1658

Informa Healthcare

Access to resources Recommend Favorite

Aprepitant an advance on standard antiemetic regimen for MEC

Inpharma, Vol. 1, Iss. 1468, 2004-01 ,pp. : 17-18

Adis International

Access to resources Recommend Favorite

Antiemetic Studies on the NK₁ Receptor Antagonist Aprepitant

By Stoutenburg John P. Raftopoulos Harry

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 2, Iss. 5, 2004-09 ,pp. : 491-497

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Bivalirudin brings benefit to treatment of STEMI

Inpharma, Vol. 1, Iss. 1661, 2008-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant

By Sankhala Kamalesh K Pandya Devesh M Sarantopoulos John Soefje Scott A Giles Francis J Chawla Sant P

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 12, 2009-12 ,pp. : 1607-1614

Informa Healthcare

Access to resources Recommend Favorite